Work

A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.1046

Authors: Adrienne Gropper Waks, Tanya Keenan, Tianyu Li, Nabihah Tayob, Gerburg M. Wulf, Edward T. Richardson, Elizabeth A. Mittendorf, Beth Overmoyer, Ian E. Krop, Eric P. Winer, Eliezer Mendel Van Allen, Judith Agudo, Sara M. Tolaney

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Merck

OpenAlex ID: W3032818918

Cites:

Cited by: 21

Related to: 10